United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.52 | 0.33 | 0.34 | -2.26 |
| FCF Yield | 6.78% | 7.26% | 5.25% | 4.92% |
| EV / EBITDA | 8.80 | 7.05 | 12.01 | 13.04 |
| Quality | ||||
| ROIC | 15.44% | 13.54% | 13.15% | 9.16% |
| Gross Margin | 89.24% | 88.94% | 92.42% | 92.73% |
| Cash Conversion Ratio | 1.11 | 0.99 | 1.10 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.11% | 11.36% | 9.29% | 5.17% |
| Free Cash Flow Growth | 44.54% | 12.64% | 39.02% | -31.45% |
| Safety | ||||
| Net Debt / EBITDA | -0.84 | -0.37 | -0.15 | -0.13 |
| Interest Coverage | 32.10 | 19.98 | 30.24 | 29.89 |
| Efficiency | ||||
| Inventory Turnover | 1.96 | 2.30 | 1.44 | 1.31 |
| Cash Conversion Cycle | 214.45 | 194.27 | 285.13 | 311.19 |